CP 532623 is primarily utilized in the field of medical research, particularly in the study of cardiovascular diseases. It functions as a potent and selective inhibitor of the enzyme soluble epoxide hydrolase (sEH), which plays a significant role in the metabolism of epoxyeicosatrienoic acids (EETs). By inhibiting sEH, CP 532623 helps to increase the levels of EETs, which are known for their anti-inflammatory, vasodilatory, and cardio-protective properties. This makes it a valuable compound in preclinical studies aimed at understanding and potentially treating conditions such as hypertension, atherosclerosis, and heart failure. Additionally, its application extends to research on inflammatory diseases and pain management, where modulating EET levels can have therapeutic benefits.